Compare LSE & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSE | RNXT |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.5M | 79.4M |
| IPO Year | 2023 | 2021 |
| Metric | LSE | RNXT |
|---|---|---|
| Price | $4.60 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.13 |
| AVG Volume (30 Days) | 2.6K | ★ 1.1M |
| Earning Date | 10-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $244.84 |
| Revenue Next Year | N/A | $195.26 |
| P/E Ratio | $61.76 | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $3.20 | $0.70 |
| 52 Week High | $6.98 | $2.59 |
| Indicator | LSE | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 47.41 |
| Support Level | $4.15 | $1.55 |
| Resistance Level | $5.09 | $1.80 |
| Average True Range (ATR) | 0.45 | 0.12 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 50.32 | 22.86 |
Leishen Energy Holding Co Ltd is a provider of clean-energy equipment and integrated solutions to the oil and gas industry, with a commitment to providing customers with high-performance, safe, and cost-effective energy solutions. The company's business segments include clean-energy equipment, oil and gas engineering technical services, new energy production and operation, and digitalization and integration equipment. A majority of its revenue is generated from the clean-energy equipment segment, which supplies various equipment, such as reciprocating compressor units, expansion units, wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment, and polymer flexible composite pipes.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.